Modern Pathology

Table 1 Pre-BRAF inhibitor patient samples and HGF immunoreactivity assessment

From: Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors

					HGF in stromal cells		HGF in tumor cells
Patient	Genotype	BRAF inhibitor	% Tumor size ^a	Site	Intensity	Extent ^b	Intensity	Extent ^b
Good responders
1	V600E	Dab	−60	LN	0	0	0	0
2	V600E	Dab	−62	SQ	0	0	1	1
3	V600E	Dab	−63	SQ	0	0	0	0
4	V600E	Dab	−63	Adrenal	0	0	0	0
5	V600E	Dab	−71	Brain	0	0	0	0
6	V600K	Dab	−67	Lung	1	1	1	1
7	V600E	Dab	−71	LN	0	0	0	0
8	V600E	Dab	−67	SQ	1	3	2	4
9	V600E	Dab	−76	SQ	0	0	0	0
10	V600E	Vem	−76	LN	0	0	0	0
11	V600E	Dab	−78	Rectum	0	0	0	0
12	V600E	Vem	−100	Muscle	0	0	3	3
Poor responders
13	V600K	Dab	10	Adrenal	1	1	1	2
14	V600E	Dab	4	LN	0	0	0	0
15	V600E	Vem	−2	Brain	0	0	1	2
16	V600E	Dab	−5	SQ	0	0	0	0
17	V600E	Dab	−6	LN	1	1	0	0
18	V600E/W604C	Dab	−6	SQ	0	0	0	0
19	V600E	Dab	−10	SQ	0	0	0	0
20	V600K	Dab	−14	SQ	0	0	0	0
21	V600E	Dab	−15	LN	0	0	0	0
22	V600E	Dab	−15	SQ	0	0	0	0
23	V600E	Vem	−17	SQ	0	0	0	0

Dab, dabrafenib; Vem, vemurafenib; LN, lymph node; SQ, subcutis.
^aMeasured according to the RECIST criteria.
^b0=no staining, 1=1–10%, 2=11–24%, 3=25–50%, and 4=>50% positive cells.

Back to article page

Search

Advanced search

Quick links